AHA 2024 - Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin – an investigational oral Lp(a) inhibitor – was investigated in patients with elevated Lp(a) levels and high CV risk.
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
AHA 2024 - Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin – an investigational oral Lp(a) inhibitor – was investigated in patients with elevated Lp(a) levels and high CV risk.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Stephen Nicholls, MD is a cardiologist, and leads the Victorian Heart Hospital (VHH) in Melbourne, Australia.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in JAMA
Release date: 19 November 2024
AHA 2024 - Stephen Nicholls shares the outcomes of the KRAKEN trial, in which the efficacy and safety of muvalaplin – an investigational oral Lp(a) inhibitor – was investigated in patients with elevated Lp(a) levels and high CV risk.
This video was recorded during the AHA Scientific Sessions 2024 in Chicago, IL, US.
Stephen Nicholls, MD is a cardiologist, and leads the Victorian Heart Hospital (VHH) in Melbourne, Australia.
This recording was developed under auspices of PACE-CME. Views expressed in the recording are those of the presenter and do not necessarily reflect the views of PACE-CME.
The findings of this study were simultaneously published in JAMA
Release date: 19 November 2024
Stay current with the best on medical education
